BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-12@catalystbrief.girapphe.com
DTSTAMP:20261117T061545Z
LAST-MODIFIED:20261117T061545Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: Bayer — Finerenone (Kerendia\, BAY94-8862) [Apr 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Learn More About How Wel
 l the Study Treatment Finerenone Works\, How Safe it is\, How it Moves Int
 o\, Through\, and Out of the Body\, and the Effects it Has on the Body Whe
 n Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children 
 With Chronic Kidney Disease and Proteinuria.\nSource: https://clinicaltria
 ls.gov/study/NCT05196035\nhttps://catalystbrief.girapphe.com/e/12?lang=en\
 nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/12?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
